Venclose is a commercial-stage medical technology company developing next-generation solutions for the treatment of venous reflux disease (chronic venous insufficiency). Its primary product, the VENCLOSE RF Ablation System, is designed to close damaged veins and restore healthy blood flow. The system is commercially available in the United States and Europe. Led by Chairman and CEO Jerry Gibson, the company plans to use recent funding to accelerate its US commercial footprint and expand globally. It also intends to invest in selective product portfolio additions. CVI is a large market, affecting more than 40 million adults in the United States, which underscores the company's commercial opportunity. Venclose, Inc. is a San Jose, CA-based medical technology company developing next-generation solutions for the treatment of venous reflux disease. The company is commercializing the VENCLOSE™ Radiofrequency (RF) Ablation System, designed to close damaged veins and restore healthy blood flow. To date, more than 4,000 patients in the United States and Europe have been treated with the VENCLOSE system. Venclose intends to use proceeds from the Series B for new product development, expansion of manufacturing capabilities and general corporate purposes. The company is led by Chairman and CEO Jerry Gibson and recently appointed Jeffrey G. Carr, MD, FACC, FSCAI as Chief Medical Officer. Gregory J. Vislocky was also appointed to the Venclose board of directors.

Total raised

$27M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2019